Alpha Tau Medical Ltd. Warrant

Alpha Tau Medical Ltd. announced the completion of enrollment of 88 patients in its ReSTART pivotal trial for treating recurrent cutaneous squamous cell carcinoma (cSCC) with Alpha DaRT®. This marks the company's first completed U.S. pivotal study and a critical milestone toward FDA pre-market approval. The company has already initiated a modula...

Alpha Tau Medical will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026, discussing recent achievements and upcoming data milestones for their Alpha DaRT cancer therapy.

The global radiopharmaceuticals market is projected to grow at a CAGR of 10.3% from 2024 to 2030, driven by the increasing prevalence of chronic diseases, advancements in imaging technology, and the transition towards personalized medicine. North America and Asia-Pacific are the key regional markets.

Alpha Tau Medical Ltd. announced the appointment of Maya Netser to its Board of Directors, while Meir Jakobsohn is stepping down from the Board but will continue to serve as an advisor.

The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat indications including skin, head & neck, and oral cavity.